Prof. dr. ir. Johannes (Hans) Tramper
has academic degrees from the Technical University Delft, NL (Chemical Engineering, 1973), from Purdue University, USA (Biochemical Engineering, 1974), from Wageningen University, NL (Ph.D. 1979) and an honorary degree from the Technical University of Lodz, PL (Doctor Honoris Causa, 2000). Since 1987 he is a full professor in the field of Bioprocess Technology at Wageningen University. He is one of the founders of the WU study Biotechnology, which started in 1990. From the start in 1979 he is a member of the European Section of Applied Biocatalysis (ESAB) of the European Federation of Biotechnology; in 2002 he was nominated the first honorary member. In 2003 he became an honorary member of the Dutch Biotechnology Society (NBV) for his continuing efforts to dissipate knowledge of biotechnology at all levels of society. He is (co-) author of over 500 papers, of which over 300 in peer-reviewed scientific journals. Since March 2007 he is on the ISI list of highly cited authors in the category Microbiology. For many years he has been in advisory boards of scientific journals (presently 5). Presently he is also coordinator of the educational program within the national B-Basic research program on industrial biotechnology.



Dr. Abraham (Bram) Bout
is since April 2007 Chief Executive Officer at Bioceros B.V. (Utrecht, The Netherlands) and Chief Technology Officer at Profibrix B.V. (Leiden, The Netherlands). From 1993 – 2007 he was employed by Crucell, where he held several positions with increasing responsibilities. From 2000 till 2007 he was as Vice President protein production responsible for manufacturing of recombinant proteins on PER.C6®. Before that, Dr. Bout was director of the adenovirus research group. One of the first achievements in this area was the generation of the PER.C6® cell line in collaboration with Leiden University and the development of that cell line into a production platform for Biopharmaceuticals. Dr. Bout’s post-doctorate work was in gene therapy for Cystic Fibrosis. Dr. Bout gained his PhD on peroxisomal storage disorders at the Academic Medical Centre in Amsterdam and studied chemistry at the University of Amsterdam, The Netherlands.




Prof. Murray Moo-Young
is a distinguished professor emeritus of Chemical Engineering at the University of Waterloo (Canada) where he has an active research program on bioprocessing and biotechnology. Murray was educated at the University of London (BSc and PhD degrees), the University of Toronto (MASc degree) and the University of Edinburgh (postdoctoral fellowship). To date, his work has produced 13 books, nine patents and over 340 journal papers. He is the editor-in-chief of the multi-volume major reference treatise Comprehensive Biotechnology and the journal Biotechnology Advances (both published by Elsevier). Murray is a consultant to industry and government agencies worldwide and his honors include the prestigious premier awards of the Canadian Society for Chemical Engineering (for commendable achievements in biochemical engineering) and the American Chemical Society, Biochemical Technology Division (for his outstanding contributions to the field). Murray Moo-Young is the founding president of the International Society for Environmental Biotechnology. He is an elected fellow of the American Institute of Medical and Biological Engineering, “one of the highest honors of bioengineers”, and the Royal Society of Canada, “the highest accolade for an academic in Canada”.